There’s been a lot of buzz around CBD these days, even before rumors that Coca-Cola is considering a CBD-infused beverage. The CBD industry has doubled in size in the last two years, and one cannabis research firm estimates that the cannabis market will reach $20 billion by 2020.

CBD products are everywhere, from topicals, capsules, oils and edibles, to sublingual tinctures. There are a whole host of health benefits to using CBD, including stopping seizures, relieving anxiety and depressions, and reducing inflammation and pain. However, with all the buzz come a lot of claims about what CBD supposedly cures. It’s still early days in cannabis and CBD research, but here’s a break down of some of the known benefits of CBD.

Seizures and Epilepsy
Earlier this year, the FDA approved Epidiolex, a cannabis-derived medication used to treat certain forms of epilepsy. The medication is literally a lifesaver for kids with two rare forms of epilepsy, and the FDA approval could open up further research into CBD.

Anxiety and Depression
There have been several studies that show CBD is effective as an anti-anxiety and antidepressant treatment. A 2011 study even found that CBD can help with social anxiety. Researchers conducted a study where people were either given CBD, a placebo, or nothing at all and compared their anxiety levels after speaking in front of a large audience. Those who were given CBD experienced less anxiety than those people given the placebo.

Psychosis
CBD could be effective in treating illnesses like bipolar disorder by acting as an antipsychotic. Traditional antipsychotic medications come with unwanted side-effects, but CBD “has a pharmacological profile similar to that of atypical antipsychotic drugs” without the downsides.

A study from earlier this year researching schizophrenia found that CBD “may represent a new class of treatment for the disorder.“

Opioid Addiction
A study published in the JAMA Internal Medicine found that there’s a significant reduction in opioid use when cannabis is an option. The study looked at data from Medicare and found that having access to cannabis resulted in reducing the number of opioid prescriptions by 3.7 million daily doses. In states that allow homegrown cannabis, there were an estimated 1.8 million fewer pills dispensed per day.

Neurodegenerative Disorders
The World Health Organization’s 2018 report on CBD found that the cannabis compound could be a therapeutic treatment for multiple sclerosis, Alzheimer’s Parkinson’s, Huntington’s disease. Another study found that CBD can reverse the iron accumulation in the brain that causes neurodegenerative disease.

The same UK-based company that makes Epidiolex also makes Sativex, a cannabis-based drug that treats spasticity in multiple sclerosis.

While studies into CBD promise to help treat wide-ranging illnesses, there is still more research that needs to be done. Luckily, high demand may pressure lawmakers to loosen restrictions around researching cannabis and CBD.

“When I first started, it was very hard to get funding or attention for researching CBD,” said Yasmin Hurd, director of the Addiction Institute at Mount Sinai Hospital. “We can’t make progress on understanding the benefits of CBD without funding and support. The more demand there is for CBD, the more I think we’ll see large-scale studies.”

In a newly released memo, the U.S. Food and Drug Administration said that cannabidiol (CBD) should be removed from the Controlled Substances Act (CSA); however, international drug treaties require the regulation of cannabis, including CBD.

The 27-page memo was written to advise the U.S. Drug Enforcement Agency (DEA) that CBD has “negligible potential for abuse,” “currently accepted medical use in treatment,” and that any abuse “may lead to limited physical dependence.”

Based on the FDA’s recommendation, the DEA rescheduled CBD under its least restrictive category, Schedule 5. Drugs in this category are considered to have a low potential for abuse and include over-the-counter medications like cough syrup containing codeine.

The FDA considered eight factors when making its scheduling recommendation and concluded that CBD “could be removed from control.”

“We reach this conclusion because we find that CBD does not meet the criteria for placement in any of Schedules II, III, IV, or V under the CSA.”

Although CBD doesn’t meet the criteria for even a Schedule 5 substance, the FDA ultimately recommended categorizing it as Schedule 5 because of a letter from Robert W. Patterson, the Acting Administrator of the DEA, “asserted that the United States would not be able to keep obligations under the 1961 Single Convention on Narcotic Drugs if CBD were decontrolled under the CSA.”

However, in the memo, the FDA notes that “if treaty obligations do not require control of CBD, or if the international controls on CBD change in the future, this recommendation will need to be promptly revisited.”

The DEA announced last Friday that FDA-approved cannabis drugs with no more than 0.1 THC would be considered Schedule 5. Currently, that only includes the recently approved epilepsy medication Epidiolex.

Canada, who is also a signatory to the Single Convention on Narcotic Drugs of 1961, will officially legalize marijuana on October 17. The International Narcotics Board, “an independent, quasi-judicial expert body” established during the 1961 treaty agreement has expressed “deep concern” over cannabis legalization. It’s not clear if Canada will withdraw from the treaty.